Kma Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 20.50%
- Profit Growth 287.87%
- Ebitda 5.41%
- Net Worth 74.38%
- Total Assets 1.94%
About Kma Pharma
Kma Pharma Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 May 2019 (Five years and nine months 15 days old ). Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Yogvir Singh and Sunder Pal serve as directors at the Company.
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24290UP2019PTC116899
- Company No.
116899
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 May 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Kma Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogvir Singh  | Additional Director | 27-Mar-2024 | Current |
| Sunder Pal | Additional Director | 03-Sep-2024 | Current |
Financial Performance of Kma Pharma.
Kma Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 20.5% increase. The company also saw a substantial improvement in profitability, with a 287.87% increase in profit. The company's net worth Soared by an impressive increase of 74.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kma Pharma?
In 2020, Kma Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jmd Consultants India Private LimitedYogvir Singh is a mutual person
Op Pharma Distributor Private LimitedYogvir Singh and Sunder Pal are mutual person
- Jaymapp International Private Limited
Yogvir Singh and Sunder Pal are mutual person
- Mvd Hospitality & Facility Management Services Private Limited
Yogvir Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kma Pharma?
Unlock and access historical data on people associated with Kma Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kma Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kma Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
